<< Back
Multiple Presentations at the European Society of Cardiology Congress Document EECP Promotes Coronary Collateral Flow Leading to Sustained Clinical Improvement

WESTBURY, N.Y.--(BUSINESS WIRE)--Sep. 1, 2009-- Vasomedical, Inc. (“Vasomedical”) (OTC: VASO), a world leader in the noninvasive treatment of cardiovascular diseases, today announced that evidence presented by Dr. Eva-Elina Buschmann on behalf of the European Arteriogenesis Network 2 Trial, at the 2009 European Society of Cardiology (ESC) Congress taking place in Barcelona, Spain, demonstrates that EECP® therapy along with its positive acute hemodynamic benefits also promotes the growth of coronary collateral blood vessels to ischemic regions improving circulation in patients with stable angina.

An oral presentation of the results of a prospective, randomized, controlled, proof-of-concept study at the ESC conducted by researchers at Charite Hospital at the University of Berlin confirmed EECP treatment promotes recruitment of new arteries. The primary end-point, using pressure-derived collateral flow index during cardiac catheterization, the gold standard to assess myocardial collateral pathways, demonstrated a significant increase of collateral perfusion to regions of the myocardium distal to coronary occlusion after EECP treatment.

“These data provide excellent evidence to support the long held hypothesis that EECP leads to increased myocardial blood flow to ischemic areas of the heart,” commented Dr. Lawrence Crawford, Associate Clinical Professor of Medicine, Division of Cardiology, Duke University School of Medicine. He continued, “This demonstrated that the increase in coronary perfusion, along with the already published scientific data demonstrating the positive hemodynamic and neurohormonal effects of EECP therapy, makes a very strong argument for the use of enhanced external counterpulsation therapy in treating stable angina and compensated heart failure patients.”

Also, presented at the ESC were three additional abstracts demonstrating the significant improvement in patient functional capacity, i.e. the sustained symptomatic relief enjoyed by patients following treatment with EECP therapy. The first study presented by Dr. Youssef A. Beaini is a multicenter study using patient data collected from four institutions in the United Kingdom - Bradford Teaching Hospitals NHS Trust in Liverpool, University of Leeds, the Cardiothoracic Centre NHS Trust in Liverpool, and the Institute for Cardiovascular Research-Yorkshire Heart Centre in Leeds. This study compared the pre- and post-EECP treatment results demonstrating significant improvement in the quality of life measurements including follow up at 6-, 12- and 24-months post therapy.

The third study presented by Dr. Stefano De Marchi, of the University of Switzerland in Berne, showed findings of improved myocardial perfusion achieved by using EECP systems specifically designed to produce high diastolic perfusion pressure during the application of therapy, confirming the need to have uniformly applied external pressure with sufficient magnitudes to produce the beneficial hemodynamic effects of counterpulsation.

The fourth study from the United States presented by Dr. Lisa Kennard, University of Pittsburgh, demonstrated a marked correlation post-EECP treatment between improvement of angina functional class expressed by Canadian Cardiovascular Society (CCS) angina classification and the Duke Activity Status Index (DASI) score which assesses functional capability in angina patients. The study showed a significant congruency in assessing functional capacity in patients with coronary artery disease and multiple comorbidities treated with EECP therapy.

“Published scientific evidence continues to demonstrate concrete evidence that the use of EECP treatment provides positive patient outcomes resulting from the recruitment of collateral blood vessels to ischemic regions, improves neurohormonal factors, improves endothelial function, reduces proinflammatory cytokines and adhesion molecules, and reduces arterial stiffness,” stated Dr. Jun Ma, president and CEO of Vasomedical. “All of these combined factors assist in the improvement of blood flow to ischemic areas and help to explain the life changing clinical benefits observed in patients that have undergone EECP therapy. We would like to congratulate the authors of these studies and thank them for their fantastic work which we believe continues to verify the hypotheses on the mechanism of actions of EECP therapy. These findings should lead to wider acceptance and broader use of EECP therapy worldwide,” concluded Dr. Ma.

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “may,” “plans,” “potential,” “should” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Source: Vasomedical, Inc.

Vasomedical, Inc.
Dr. Jun Ma, President and CEO, 516-997-4600
or
David Singh, CFO, 516-997- 4600
or
Investor Relations:
customerservice@vasomedical.com

Could not find file '\\aws.nasdaqomx.com\irwebpro\content3\IRXMLDATA\95\95266\Disclaimers.xml'.